



Supplementary Table 1. Antibody levels measured by ELISA, sVNT and PRNT against ancestral SARS-CoV-2 virus and the Omicron variant at Day 0 and 28 after third-dose BNT162b2 vaccination, in 20 randomly selected participants who previously received two doses of inactivated COVID-19 vaccine. D0: Day 0 (baseline); D28: Day 28 (post-vaccination); ELISA: enzyme-linked immunosorbent assay; sVNT: surrogate virus neutralisation test; PRNT: plaque reduction neutralisation test; PRNT₅₀: 50% plaque reduction neutralization titer; PRNT₉₀: 90% plaque reduction neutralization titer; GMT: geometric mean titer.

	Ancestral SARS-CoV-2 virus								Omicron variant			
	ELISA Spike RBD IgG (OD ₄₅₀)		sVNT % inhibition (%)		PRNT ₅₀ titer		PRNT ₉₀ titer		PRNT ₅₀ titer		PRNT ₉₀ titer	
	D0	D28	D0	D28	D0	D28	D0	D28	D0	D28	D0	D28
1	0.2	1.7	20	94	<10	160	<10	40	<10	<10	<10	<10
2	0.1	2.6	0	97	<10	≥320	<10	≥320	<10	10	<10	<10
3	1.2	1.9	6	97	<10	≥320	<10	160	<10	20	<10	10
4	0.1	1.9	3	97	<10	≥320	<10	160	<10	40	<10	10
5	0.2	1.9	14	97	<10	≥320	<10	160	<10	80	<10	40
6	0.3	2.0	30	97	<10	≥320	<10	≥320	<10	80	<10	20
7	0.1	1.8	0	96	10	160	<10	40	<10	20	<10	10
8	0.2	2.7	23	97	10	≥320	<10	≥320	<10	20	<10	10
9	0.7	1.5	42	97	10	≥320	<10	≥320	<10	40	<10	10
10	0.2	1.9	0	97	10	≥320	<10	≥320	<10	40	<10	10
11	0.5	1.7	48	91	10	≥320	<10	≥320	<10	160	<10	40
12	0.2	2.1	19	98	10	≥320	<10	80	<10	≥320	<10	160
13	0.2	1.8	23	97	20	≥320	<10	160	<10	20	<10	<10
14	0.2	1.7	28	97	20	≥320	<10	160	<10	40	<10	10
15	0.2	1.9	6	97	20	≥320	<10	≥320	<10	≥320	<10	80
16	0.2	2.0	5	97	20	≥320	<10	≥320	10	40	<10	20
17	0.4	1.7	37	97	40	≥320	10	≥320	<10	80	<10	20
18	0.2	2.8	29	97	40	≥320	10	≥320	<10	80	<10	20
19	0.7	2.0	44	97	40	≥320	10	≥320	<10	160	<10	40
20	0.2	1.9	36	97	40	≥320	10	≥320	<10	≥320	<10	160
Mean*	0.3	2.2	17	96	12	557	6	309	5	59	5	19


*Note: For PRNT₅₀ or PRNT₉₀ mean titers, we estimated the geometric mean titer (i.e. GMT) by imputing titers <10 with the value 5 and titers ≥320 with the value 640.



Supplementary Figure 1. Flow chart for this single-arm, open-label clinical trial of BNT162b2 provided as a third vaccine dose in adults who previously received two doses of inactivated COVID-19 vaccine.



Supplementary Figure 2. ELISA and sVNT antibody levels in 20 participants randomly selected to be tested by PRNT compared to all vaccinated participants with paired Day 0 and Day 28 sera collected. (A) ELISA for serum IgG against SARS-CoV-2 Spike receptor binding domain (RBD) of ancestral strain. (B) Surrogate virus neutralization test (sVNT) against ancestral strain. X indicates the mean level. All: all vaccinated participants with paired Day 0/Day 28 sera collected (N = 312); Selected: participants randomly selected to be tested by PRNT (N = 20).



Supplementary Figure 3. Correlation of PRNT₉₀ titers measured at Day 28 against ancestral strain and the Omicron variant in 20 participants randomly selected for performing PRNT. PRNT titers are measured based on two-fold dilutions and plotted here within an interval, or <10 (plotted on axis) or ≥320 (plotted above 320). r: Spearman’s rank correlation coefficient; p: p-value.